Discover a new way to find and share stories you'll love… Learn about Reading Desk

Blog Profile / In the Pipeline

Filed Under:Medical / Pharmaceutical
Posts on Regator:2012
Posts / Week:9.3
Archived Since:November 3, 2010

Blog Post Archive

Holiday Blogging: Gingersnaps

As I type this, I am eating one of these cookies, so that should be an endorsement. We often make these during the holidays - I found the the recipe online about fifteen years ago (source lost, as you'd figure, even if it's still up somewhere), and it's been a reliable performer. Show More Summary

Holiday Blogging 2014

As of today, posting will be irregular around here until New Year's. I'm not going to disappear entirely (I still have some things backed up to write about), but the holiday season will slow things down. And I promise, as has been the practice here, to post a recipe or two, since cooking is the next thing to chemistry.

AbbVie Competes on Price

Well, folks, if you wonder where the price-cutting competition is in the drug industry, it's here. AbbVie is competing with Gilead in the (very lucrative) hepatitis C market, and since Gilead had already staked out a big position, AbbVie...Show More Summary

Merck, Cubist, and Hospira: The Inside

Or as much of the inside as we're likely to have. Thanks to @AndyBiotech on Twitter, here's an SEC document detailing the negotiations between Merck and Cubist. It makes for interesting reading in general - you can see how a deal like...Show More Summary

Another Alzheimer's Antibody Goes Down

The clinical failure rate for disease-modifying Alzheimer's therapies remains perfect, unfortunately: a flat 100%. The latest news is from Roche. Their in-licensed amyloid-targeting antibody (gantenerumab, from MorphoSys) came up empty on an interim trial analysis. Show More Summary

Nativis In the Clinic

Time to revisit an old favorite around here. Remember Nativis Pharmaceuticals? I do, since they provided one of my most treasured "you can expect legal action" letters. When last mentioned here, they were working on the "Voyager", aShow More Summary

What Would You Put In a Med-Chem Textbook?

I had an interesting note this morning from a reader who's been asked about writing an introductory textbook on medicinal chemistry. He's been looking over the field, and wondering what to include (and what to leave out). Quite a few...Show More Summary

Actavis and Namenda

John LaMattina has a column at Forbes about the situation with Actavis and their Alzheimer's drug, Namenda (memantine). That situation is not a pretty one: the company has an extended-release form of the drug coming on, which they believe will be more convenient to dose. Show More Summary

J. Already Known Chem.

A reader sent along this paper, which recently appeared in JACS. He'd read it and was puzzled - not by the content of the paper, but as to "how it got into JACS". So I had a look. It's on the peptide hormone oxyntomodulin, a 37-residue species closely related to glucagon which stimulates insulin release as an agonist at the GLP-1 receptor. Show More Summary

Science Gifts 2014: Experiments at Home

This is a repost of a "Science Gifts" suggestion from last year - from what I can see, the field hasn't had any major additions in the past few months, and the recommendations below are all still relevant. Interesting science-gift ideas can be found in the "home experiments" area. Show More Summary

Best and Worst Biotech CEO Time

I always enjoy Adam Feuerstein's voting for Best and Worst CEO in the biotech industry. But just as number of people who've read Dante's Inferno far outnumber the ones who've read the Paradisio (I'm a halfway through the Purgatorio guy myself), I suspect that more people read and vote on the Worst CEO part. Show More Summary

More Designer Drugs

Here's a good article on the illegal recreational drug trade - the boutique end of it, anyway. I've written about this sort of thing before, and this piece is squarely in the same territory (even to interviewing David Nichols). It all...Show More Summary

Cells In Disguise

This is a good read for anyone who's depending on cell assays to tell them something useful. Longtime cell biologists will know that there have been several upheavals over the years about misidentified or contaminated cell lines. HeLa...Show More Summary

Our Disorganized Piles of Chemical Information

Here's a good look (by an all-star cast of authors) at the availability of pharmaceutical chemistry data in accessible databases. There are several points made. For one, there is far more publicly available information than ever before, and its total looks to outstrip the proprietary databases (such as CAS/SciFinder). Show More Summary

Guidelines For MOF Crystallography

There's a new and very useful paper out on the "molecular sponge" technique for crystallography (first blogged about here, with updates here and here). It's from the Clardy group at Harvard with collaboration from Argonne, in Acta Crystallographica,...Show More Summary

Daiichi Sankyo Will Pay You A Million Dollars

Daiichi Sankyo is apparently crowdsourcing ideas for anti-obesity drug discovery. See this page at NineSigma. The requirements are that the submitted idea: Must be a new anti-obesity drug candidate or drug target Exhibit superior anti-obesity...Show More Summary

NMR of a Mass Spec Species

I have to say, I didn't even know that this could be done. This paper from Angewandte Chemie describes a mass spec/NMR combination analysis that had never occurred to me as possible. The authors (from Ohio U. and Purdue) are looking at a common peptide ion seen in proteomic mass spec studies. Show More Summary

Who Owns CRISPR?

CRISPR/Cas9 is an excellent technique for gene manipulation. Its discovery is absolutely going to be the subject of a Nobel prize; I think it's pretty much of a lock. But at the moment, there's a vicious legal fight going on over who owns the right to it. Show More Summary

A New Route to Spiro Heterocycles

For fans of saturated nitrogen heterocycles (and there are many in med-chem), this paper is well worth a look. It's from Jeffrey Bode's group at the ETH in Zürich (authors of a recent review in this area), and it's another version of their "SnAP" chemistry, tin-mediated conditions for ring formation. Show More Summary

A New Effect From JAK Inhibition

Here's an interesting paper for people into metabolic disease: the authors report that JAK1/3 inhibitors (such as ?tofacitinib) seem to cause human adipocytes to convert from their normal phenotype into brown fat, a different beast altogether. Show More Summary

Copyright © 2011 Regator, LLC